Combinations work better

Share this content:
Combinations work better
Combinations work better

Researchers have found that combination therapy, including those involving experimental treatment agents, may help treat patients with advanced breast cancer, according to multiple reports presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Two of the presented studies focused on the experimental treatment trastuzumab-DM1 (T-DM1) and demonstrated its effectiveness for women with advanced HER2-positive breast cancers.

The findings of one study, presented by Kathy Miller, MD, associate professor of medicine at the Indiana University Melvin and Bren Simon Cancer Center, found that T-DM1 with or without pertuzumab has some effectiveness for women with advanced HER2-positive breast cancers previously treated with trastuzumab.

A second study, led by Patricia LoRusso, DO, professor of medicine at the Karmanos Cancer Institute, found that retesting a breast cancer tumor for possible changes in HER2 expression could predict the effectiveness of T-DM1. "This agent is beginning to stand out as a treatment for women who have been heavily pretreated for metastatic breast cancer," noted Sumanta Pal, MD, assistant professor of oncology at the City of Hope Comprehensive Cancer Center.

Adding everolimus (Afinitor) to the chemotherapy regimen of women with metastatic breast cancer may result in clinical benefits, according to another study presented by Fabrice Andre, MD, assistant professor of medicine at the Institute Gustav Roussy, France. He and other researchers found that everolimus lessens the resistance to treatment in patients whose cancer is no longer sensitive to paclitaxel and trastuzumab. "These are interesting studies that show combining everolimus with chemotherapy and other target agents is feasible with promising results," said Edith Perez, MD, professor of medicine at the Mayo Clinic.

Another study on everolimus, presented by P.K. Morrow, MD, assistant professor of medicine at the University of Texas M.D. Anderson Cancer Center, found that adding everolimus to therapy resulted in clinical benefit for more than one-third of patients. The findings supported the results from Dr. Andre's study.

The collective results show that combination therapy is feasible and add to evidence supporting effective treatments for advanced breast cancer patients. ONA

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs